Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)
Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.Peer-Reviewed Original ResearchOverall survivalCHRT groupLate toxicityMucosal toxicityAcute mucosal toxicityHigher daily doseTumor registry dataOverall treatment timeDefinitive chemoradiationAcute mucositisConcurrent chemoradiationAdvanced headCompliant patientsLess weight lossRandomized studySkin necrosisCisplatin chemoradiationDaily doseDistant metastasisPatient chartsNeck cancerAltered fractionationRadiation fractionationRegistry dataNonsignificant decrease